CVAC News and Press, CureVac N.V. From 01/31/23

CureVac recognized as a Top 100 innovator in acknowledgment of the company's innovative strength and extensive intellectual property portfolio The company holds one of broadest intellectual property portfolios in mRNA technology TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / Janua...

CureVac ( NASDAQ: CVAC ) is trading 5.6% higher premarket after it announced positive data from its Phase 1 trial of its vaccine candidate, CV0501, to treat COVID-19 in collaboration with GSK. The data showed that monovalent modified mRNA construct CV0501 boosted ant...

Continued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and flu COVID-19: monovalent modified mRNA construct CV0501 successfully boosted antibody titers against BA.1 and ancestral variants in adults age ≥65 ...

Summary The explosive growth in mRNA technology is giving us all a chance to watch a scientific field advance in real time. Since its founding, CureVac had stuck with the hypothesis that uridine modification wasn’t actually necessary for an effective vaccine, so long as one took ...

Shares of CureVac BV ( NASDAQ: CVAC ) have already almost doubled year-to-date but a UBS analyst says the stock still has a lot more room to the upside. CureVac stock could gain close to 100% On Thursday, Eliana Merle turned bullish on the biopharmaceutical firm and sharply increased ...

CureVac N.V. ( NASDAQ: CVAC ) added ~9% pre-market Thursday after UBS upgraded the German biotech to Buy from Neutral, citing the Phase 1 data the company recently released for the mRNA-based COVID-19 and flu shots it co-develops with GSK ( GSK ). The early readouts for vaccin...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Following the Monday holiday, the equities sector got off to a slow start for the Jan. 17 session, with Pfizer (NYSE: PFE ) conspicuously declining more than 3% in the early afternoon hours. Unfortunately for the pharmaceut...

Shares of CureVac (NASDAQ: CVAC) rose as much as 19.1% on Tuesday. The stock closed at $10.36 on Monday, then rose to as high as $12.43 in the late afternoon on Tuesday. It was the third consecutive day the stock was higher than the day before. Despite the rise, CureVac is down more t...

CureVac N.V. ( NASDAQ: CVAC ) rose for the third straight session on Tuesday, extending recent gains made from encouraging early-stage data for its mRNA-based vaccines and following the appointment of Sanofi ( SNY ) executive Alexander Zehnder as its new CEO. CureVac ( CVAC ) ...

Dr. Franz-Werner Haas to complete successful tenure as CEO by March 31, 2023 Dr. Alexander Zehnder to succeed Dr. Haas as new CEO, joining from Sanofi on April 1, 2023 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 9, 2023 / CureVac N.V. (NASDAQ:CVAC), a global biopha...